跳至主要内容
临床试验/NCT05450081
NCT05450081已完成不适用

Clinical Trials to Evaluate the Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients With Non-small Cell Lung Cancer

Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2022年6月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
140
试验地点
1
主要终点
Consistency

研究概览

简要总结

Our study aimed to evaluate the correlation between test reagent specific gene test results and the efficacy of relevant targeted drugs in patients with non-small cell lung cancer, and to support the continued registration of test reagents.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18,advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy.
  • Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case

排除标准

  • Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells >20%);
  • Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs;
  • Maintenance treatment when the disease does not progress after other anti-tumor treatments.

结局指标

主要结局

Consistency

时间窗: October 2022-December 2022

he consistency of efficacy between specified kit and 22C3

PFS

时间窗: October 2022-December 2022

Progression free survival time

ORR

时间窗: October 2022-December 2022

Objective response rate

次要结局

未报告次要终点

研究者

发起方
Hunan Province Tumor Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yongchang Zhang

Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Hunan Province Tumor Hospital

研究点 (1)

Loading locations...

相似试验

Association Between the Results of Specific Genetic... | 临床试验